Summary of COVID-19 MIB-626 studies

1. Pencina et al., Oral MIB‐626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID‐19 and Acute Kidney Injury: A Randomized Controlled Trial

39 patient MIB-626 late treatment RCT: 156% higher mortality (p=1) and 18% improved recovery (p=0.71).
RCT 42 hospitalized patients with COVID-19 and acute kidney injury (AKI) showing no clinical benefit with MIB-626 (β-nicotinamide mononucleotide) treatment. The study found that 1.0g of MIB-626 twice daily safely and significantly raised blood NAD+ levels, but this did not result in any significant difference in the primary endpoint (serum creatinine). Furthermore, there were no significant differences in secondary endpoints, including other markers of AKI (cystatin C, NGAL, KIM-1), inflammation (CRP, IL-6, TNFa), or overall clinical disease severity.
Jun 2025, FASEB BioAdvances, https://faseb.onlinelibrary.wiley.com/doi/10.1096/fba.2025-00014, https://c19p.org/pencina